Using oncolytic viruses to improve treatment and imaging for pancreatic cancer
Advancing Systematic Delivery of Oncolytic Adenovirus for Pancreatic Cancer
This study is exploring a new way to treat pancreatic cancer using special viruses that can attack cancer cells and help doctors see how well the treatment is working, and it's designed to help patients by making therapies more effective and improving how their progress is tracked.
Quick facts
| Grant type | R01 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | University of Minnesota NIH-funded |
| Lab location | 1 site (Minneapolis, United States) |
| Project ID | NIH-10874733 on NIH RePORTER |
What this research studies
This research focuses on developing a new treatment approach for pancreatic ductal adenocarcinoma (PDAC) using oncolytic adenoviruses that can both target cancer cells and enhance imaging techniques. The project aims to create a swine model that can better mimic human responses to these therapies, as current animal models are inadequate. By using a specific type of adenovirus that can induce uptake of radioactive iodine, the research seeks to improve both the diagnosis and treatment of this challenging cancer. Patients may benefit from more effective therapies and better monitoring of their disease progression.
Who could benefit from this research
Good fit: Ideal candidates for this research are individuals diagnosed with pancreatic ductal adenocarcinoma who are seeking innovative treatment options.
Not a fit: Patients with other types of cancer or those who do not have pancreatic ductal adenocarcinoma may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could lead to more effective treatment options and improved diagnostic capabilities for patients with pancreatic cancer.
How similar studies have performed: While the use of oncolytic viruses in cancer treatment is a growing field, this specific approach using a swine model for pancreatic cancer is relatively novel and has not been extensively tested.
Where this research is happening
Minneapolis, United States
- University of Minnesota — Minneapolis, United States (Active)
Researchers
- Principal investigator: Davydova, Julia — University of Minnesota
- Study coordinator: Davydova, Julia
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.